Ocular adverse events in PD-1 and PD-L1 inhibitors

BACKGROUND: Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors can cause unique immune-related adverse effects due to non-specific immunological activation. However, less is known about adverse effects of these drugs in the eye. METHODS: Two adverse event databases were retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, LeAnne, Finnigan, Shanda, Streicher, Howard, Chen, Helen X, Murray, James, Sen, H Nida, Sharon, Elad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258670/
https://www.ncbi.nlm.nih.gov/pubmed/34226280
http://dx.doi.org/10.1136/jitc-2020-002119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258670/
https://www.ncbi.nlm.nih.gov/pubmed/34226280
http://dx.doi.org/10.1136/jitc-2020-002119

Ejemplares similares